PT - JOURNAL ARTICLE AU - Chowdhury, Mohammad Mihrab AU - Islam, Md Rafiul AU - Hossain, Md Sakhawat AU - Tabassum, Nusrat AU - Peace, Angela TI - Incorporating the mutational landscape of SARS-COV-2 variants and case-dependent vaccination rates into epidemic models AID - 10.1101/2021.11.28.21266882 DP - 2021 Jan 01 TA - medRxiv PG - 2021.11.28.21266882 4099 - http://medrxiv.org/content/early/2021/11/29/2021.11.28.21266882.short 4100 - http://medrxiv.org/content/early/2021/11/29/2021.11.28.21266882.full AB - Coronavirus Disease (COVID-19), which began as a small outbreak in Wuhan, China in December 2019, became a global pandemic within months due to its high transmissibility. In the absence of pharmaceutical treatment, various non-pharmaceutical interventions (NPIs) to contain the spread of COVID-19 brought the entire world to a halt. After almost a year of seemingly returning to normalcy with the world’s quickest vaccine development, the advent of more infectious and vaccine resistant coronavirus variants is bringing the situation back to where it was a year ago. In the light of this new situation, we conducted a study to portray the possible scenarios based on the three key factors : impact of interventions (pharmaceutical and NPIs), vaccination rate, and vaccine efficacy. In our study, we assessed two of the most crucial factors, transmissibility and vaccination rate, in order to reduce the spreading of COVID in a simple but effective manner. In order to incorporate the time-varying mutational landscape of COVID-19 variants, we estimated a weighted transmissibility composed of the proportion of existing strains that naturally vary over time. Additionally, we consider time varying vaccination rates based on the number of daily new cases. Our method for calculating the vaccination rate from past active cases is an effective approach in forecasting probable future scenarios as it actively tracks people’s attitudes toward immunization as active cases change. Our simulations show that if a large number of individuals cannot be vaccinated in a short period of time, adopting NPIs is the best approach to manage disease transmission with the emergence of new vaccine breakthrough variants and more infectious variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.